F901318

DRUG7 trials

Sponsors

F2G Biotech GmbH

Conditions

Acute Myeloid LeukemiaInvasive AspergillosisPulmonary Aspergillosis - Invasive

Phase 1

F901318 Single Ascending Dose Study in Healthy Male Volunteers

CompletedNCT02142153

F2G Biotech GmbHInvasive Aspergillosis

Start: 2014-08-31End: 2014-10-31Updated: 2015-09-07

F901318 Multiple Ascending Dose Study

CompletedNCT02342574

F2G Biotech GmbHInvasive Aspergillosis

Start: 2015-02-28End: 2016-09-30Updated: 2016-09-19

Study of Potential for Interaction of Fluconazole With F901318

CompletedNCT02730442

F2G Biotech GmbHInvasive Aspergillosis

Start: 2016-02-29End: 2016-06-30Updated: 2017-02-02

Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients

WithdrawnNCT02856178

F2G Biotech GmbHAcute Myeloid Leukemia, Pulmonary Aspergillosis - Invasive

Start: 2017-04-20End: 2017-04-20Updated: 2018-02-15

Pharmacokinetics of IV Formulation

WithdrawnNCT03076905

F2G Biotech GmbHInvasive Aspergillosis

Start: 2017-05-31End: 2017-08-31Updated: 2017-11-01

Drug/Drug Interactions With F901318

WithdrawnNCT03095547

F2G Biotech GmbHInvasive Aspergillosis

Start: 2017-05-31End: 2017-10-31Updated: 2017-11-01

Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects

CompletedNCT03340597

F2G Biotech GmbHInvasive Aspergillosis

Start: 2017-12-12End: 2018-04-13Updated: 2018-08-02

Related Papers

Evaluation of the cytochrome P450-mediated drug interaction profile of olorofim.

2026-04-20